Vaccine-Derived Neutralizing Antibodies Targeting Pentameric Complex
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine strategies for human cytomegalovirus (HCMV) lack effective neutralizing antibodies, particularly against congenital infections, due to incomplete understanding of correlates of protection and limited animal models, leading to inadequate prevention of HCMV vertical transmission and infections in transplant recipients.
Innovation Solution
Development of vaccine-derived neutralizing antibodies (NAbs) targeting the pentameric complex (PC) comprising gH, gL, UL128, UL130, and UL131A, which mimic naturally induced antibodies in specificity and potency, and small peptides representing linear epitopes on UL128 for enhanced immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vaccine strategies focus on stimulating NAbs targeting major envelope glycoprotein B (gB), then moderate efficacy (38-50%) is achieved in preventing primary infection, but the efficacy is insufficient to prevent congenital HCMV infection and vertical transmission
Solution Approach 1:
The invention segments the vaccine target into multiple glycoprotein components (gB, gH, gL, UL128, UL130, UL131A) that form the pentameric complex. By targeting the complete PC complex rather than just gB alone, the vaccine stimulates a more comprehensive NAb response that addresses multiple entry routes into host cells, thereby improving reliability while maintaining productivity.
Solution Approach 2:
The vaccine employs a composite antigen structure comprising multiple glycoproteins (gB, gH, gL, UL128, UL130, UL131A) assembled into the pentameric complex. This composite structure mimics the native viral entry complex and elicits a more robust and broadly neutralizing antibody response, achieving both high reliability and effectiveness against congenital infection.
2Reliability
If vaccine approaches use purified proteins or viral vector systems targeting the pentameric complex, then high titer EpC/EnC specific NAb responses are elicited, but the ability to prevent fibroblast entry remains less potent
Solution Approach 1:
The vaccine design accepts that different cell types require different levels of protection. The pentameric complex vaccine produces high-titer NAbs that are particularly potent against EpC/EnC entry (the more dangerous route for congenital infection), while maintaining some protection against FB entry. This localized optimization of protection quality matches the relative risk profile of different cell types.
Solution Approach 2:
The pentameric complex serves as a universal target that addresses multiple cell type infections. The PC is involved in entry into both EpC/EnC and FB, so a single vaccine targeting PC provides multi-functional protection across different cell types, though with varying potency levels appropriate to the risk profile of each cell type.
3Measurement precision
If NAbs target conformational epitopes formed by UL128/130/131A subunits of the pentameric complex, then dramatically superior potency is achieved in interfering with EpC/EnC infection, but these NAbs are unable to prevent fibroblast entry
Solution Approach 1:
The vaccine elicits NAbs with locally optimized quality for the most critical infection route. Conformational epitopes on the PC subunits generate NAbs with dramatically superior potency against EpC/EnC entry, which is the primary concern for congenital infection prevention. The reduced activity against FB entry is acceptable given the lower risk profile of FB infection.
Data Source
AI summary
Vaccine-derived neutralizing antibodies (NAbs) for CMV infections and small peptides which define precise recognition elements of the antigens by the NAbs. The vaccine-derived NAbs may be produced by immunizing a subject with a gH/gL/UL128/UL130/UL131A pentameric glycoprotein complex (gH/gLPC). The vaccine-derived NAbs may have properties similar or identical to those of NAbs induced in a subject naturally infected with CMV. Native and non-native small peptides from UL128 and gH have been defined by mapping epitopes and deriving artificial sequences which are minimal recognition elements of vaccine-derived NAbs. These small peptides can be used to elicit vaccine-derived NAbs that prevent CMV entry into susceptible cell types and protect humans from infection and disease. Multivalent vaccines comprising these small peptides and/or epitopes as well as methods of using the vaccine-derived NAbs and small peptides for treating or preventing CMV infection in a subject are also provided.